Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.10 Consensus Target Price from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been assigned an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.10.

RXRX has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Morgan Stanley increased their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Finally, Bank of America reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total value of $110,400.00. Following the completion of the sale, the director owned 6,169,863 shares of the company’s stock, valued at approximately $22,705,095.84. This trade represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 117,974 shares of company stock valued at $408,971. 6.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Brighton Jones LLC lifted its holdings in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after acquiring an additional 6,699 shares during the period. Royal Bank of Canada lifted its holdings in Recursion Pharmaceuticals by 627.6% in the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after acquiring an additional 232,038 shares during the period. AQR Capital Management LLC acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Recursion Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after acquiring an additional 12,372 shares during the period. Finally, Focus Partners Wealth acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at $77,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $3.18 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. The stock has a fifty day moving average price of $3.32 and a 200 day moving average price of $3.76. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18. The company has a market cap of $1.69 billion, a PE ratio of -2.65 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. During the same period last year, the company earned ($0.50) earnings per share. The company’s revenue for the quarter was down 56.8% on a year-over-year basis. Sell-side analysts forecast that Recursion Pharmaceuticals will post -0.99 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.